---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002073"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:07:10.383227+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Protagonist updates pipeline: rusfertide Ph3 enrollment Q1 2024; JNJ-2113 Ph3 psoriasis data Nov 2024

## Summary
- Rusfertide Phase 3 VERIFY study enrollment completion expected Q1 2024; primary endpoint similar to Phase 2.
- Phase 2 REVIVE showed 69.2% responder rate vs 18.5% placebo (p=0.0003); durable Hct control to 2.5 years.
- Rusfertide improved fatigue (p=0.0074) and concentration (p=0.0018) scores; ferritin normalized over 2.5 years.
- JNJ-2113 Phase 3 ICONIC-LEAD psoriasis primary completion ~Nov 2024; Phase 2b ANTHEM UC completion ~Nov 2024.
- Anticipated rusfertide NDA filing Q4 2026; JNJ-2113 NDA filing expected 2025/2026.

## SEC filing metadata
- accession: 0001104659-24-002073
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465924002073/0001104659-24-002073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465924002073/tm242310d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002073
- JSON: https://secwatch.observer/filing/0001104659-24-002073.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.